Cristina R. Antonescu

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

142h-index72.6kcitations1.2kworks1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(673), Gastrointestinal Tumor Research and Treatment(311), Vascular Tumors and Angiosarcomas(137), Cardiac tumors and thrombi(132), Neurofibromatosis and Schwannoma Cases(100)

Publications1.2k total

Uterine Sarcomas Harbouring Novel FOXO1 Gene Rearrangements
The American Journal of Surgical Pathology·2025
FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from <i>PLAG1</i> -Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Clinical Cancer Research·2025Open Access
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Cancer Research Communications·2025Open Access
Expanding the Morphologic and Molecular Spectrum of Spindle Cell Tumors Associated With <scp>TERT</scp> Fusions
Genes Chromosomes and Cancer·2025
Supplementary Tables S1-S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
2025Open Access
Supplemental Figure 3 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in &lt;i&gt;PDGFRA D842V&lt;/i&gt;-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplementary Figure S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
2025Open Access
Supplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
Supplementary Figure S1 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
2025Open Access
Supplemental Figure 5 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in &lt;i&gt;PDGFRA D842V&lt;/i&gt;-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 1 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in &lt;i&gt;PDGFRA D842V&lt;/i&gt;-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 7 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in &lt;i&gt;PDGFRA D842V&lt;/i&gt;-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 6 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in &lt;i&gt;PDGFRA D842V&lt;/i&gt;-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplementary Figure S2 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
2025Open Access
Supplemental Figure 8 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in &lt;i&gt;PDGFRA D842V&lt;/i&gt;-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplemental Figure 2 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in &lt;i&gt;PDGFRA D842V&lt;/i&gt;-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplementary Figure S3 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
2025Open Access
Supplemental Figure 4 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in &lt;i&gt;PDGFRA D842V&lt;/i&gt;-Mutant Gastrointestinal Stromal Tumor
2025Open Access
Supplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
page 1 of 62Next →

Frequent Co-authors

Samuel Singer(19), Marc Ladanyi(17), Robert G. Maki(17), Murray F. Brennan(15), Ronald P. DeMatteo(8), Christopher D.�M. Fletcher(7), Julia A. Bridge(6), Peter Besmer(5), James M. Woodruff(5), John H. Healey(5), Jonathan A. Fletcher(4), George D. Demetri(4), Paola Dal Cin(4), Tianhua Guo(4), Yun Shao Sung(4), William D. Tap(4), Gary K. Schwartz(4), Pedram Argani(4), Jordi Barretina(3), Scott M. Schuetze(3)